

Education

- Undergraduate degree : Medical Faculty, University Of Hong Kong (1988-93)
- Doctor of Medicine: Medical Faculty, University Of Hong Kong (2007)
- Overseas training on cancer biology : Cleveland Clinic Foundation, USA (2000-01)

Qualifications

- M.B.,B.S. (HK):1993; M.D. (HK): 2007; MRCP (UK):1996; FHKCP (Respiratory Medicine):2001; FHKAM (Medicine) 2001; FRCP (Glasg) 2008; FRCP (Edin) 2009; FRCP (Lond) 2010; FAPSR 2012

Professional memberships

- **Hong Kong Thoracic Society (President 2011-13, Scientific and Educational Subcommittees, Editor-in-chief of newsletter 2003-2005, Honorary Treasurer 2005-2009, Honorary Secretary 2009-11), Hong Kong Lung Foundation (Executive Board member since 2009; Honorary secretary 2017-19), American College of Chest Physicians (FCCP), Asian-Pacific Society of Respiriology (member since 2001, member of Research Committee since 2006, fellow since 2012), International Association for the Study of Lung Cancer (IASLC) (member since 2006, member of Education Committee 2013-2017, member of Membership Committee since 2015)**

Key working experience and appointments

- **Clinical Associate Professor**, University Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong (since Jan 2014)
- **Honorary Consultant**, Department of Medicine, Queen Mary Hospital, Hong Kong (since Mar 2014)
- Clinical Assistant Professor, University Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong (May 2006 – Dec 2013)
- Specialist in respiratory medicine, Queen Mary Hospital

- Subspecialty board in Respiratory Medicine, Hong Kong College of Physicians: board member (since 2013)
- Scientific Committee member, Hong Kong College of Physicians: since 2014
- Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster: deputy chairman (since 2013)

Editorial board members

- ISRN Pulmonology (open access journal, Hindawi Publishing Corporation): member of editorial board since 2011
- Advances in Lung Cancer (open access journal, Scientific Research Publishing): member of editorial board since 2012
- Clinical Cancer Drugs (open access journal, Benthamscience Publishers): member of editorial board since 2012
- Clinical Pulmonary Medicine (Lippincott Williams & Wilkins, ISBN/ISSN: 10680640): member of editorial board since 2012
- Seminars in Respiratory and Critical Care Medicine (Thieme Medical Publishers, ISSN 1069-3424): member of editorial board since 2012
- International Scholarly Research Notices (open access journal, Hindawi Publishing Corporation): member of editorial board since Mar 2014
- Respirology Case Reports: Associate Editor since June 2016

Research areas

1. Preclinical development of novel drug treatments for lung cancer: arsenic trioxide, autophagy inhibitor, pegylated arginase
2. Clinical trials for non-small cell lung cancer
3. Antioxidants in lung cancer: expression profiles, gene polymorphisms
4. Functional and ultrastructural study of respiratory cilia
5. Epidemiology studies on asthma

Experience with clinical trials

1. Multicentre phase II trial on docetaxel and cisplatin in advanced non-small cell lung cancer (1998-2000): Co-investigator
2. Single-centre phase II trial on vinorelbine in elderly advanced non-small cell lung cancer (2002-2003): Co-investigator
3. Multicentre phase III trial on Tarceva in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer (2002-2003): Co-investigator
4. Multicentre phase II study of Ro 50-3821 in anaemic patients with stage IIIB or IV non-small cell lung carcinoma receiving antineoplastic therapy (2004-2005): Principal investigator
5. Single-centre phase II study of combination of Irinotecan and Cisplatin in Docetaxel/Cisplatin-responsive advanced non-small cell lung cancer (2005-2006): Principal investigator
6. Multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer, who have not received prior chemotherapy (2005-2008): Principal investigator
7. Multicentre phase II marker identification trial for Tarceva in second line NSCLC patients-MERIT (2005-2008): Principal investigator

8. A 12-week, double-blind, randomized study to investigate the effect of 500µg roflumilast tablets once daily versus placebo on pulmonary function in patients with chronic obstructive pulmonary disease (2005-2007): Principal investigator
9. International, Randomized, Open-Label, Phase 3, Trial of Paclitaxel/Carboplatin Plus PF-3512676 Versus Paclitaxel/Carboplatin Alone As First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (2006-2008): Principal investigator
10. A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy (2006-2007): Principal investigator
11. A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients with Locally-Advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-cancer Therapy (2007-2012): Principal investigator
12. A randomized, double blind, placebo controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for the first line treatment of locally advanced, recurrent, or metastatic Non-Small Cell Lung Cancer (2007-2010): Principal investigator
13. A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination with Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer (2007-2012): principal investigator
14. A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Cisplatin Chemotherapy (2008-2009): Principal investigator

15. A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin-based chemotherapy (gemcitabine or paclitaxel) (2008-2011): Principal investigator
16. Multicenter, randomized, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in patients with stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy (2009-2012): Principal investigator
17. A randomised, placebo-controlled, double-blind phase III study of sequential administration of Tarceva® (erlotinib) or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) (2009-2014): Principal investigator
18. A Phase III, multi-center, placebo-controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens for advanced disease (2009-2012): Principal investigator
19. Phase 2, open-label single arm study of the efficacy and safety of PF-02341066 in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus (2010-2016): Principal investigator
20. Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced non-small cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus (2010-2016): Principal investigator

21. Randomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment (2011-2013): Principal investigator
22. A randomized, double-blind, phase 2 study of erlotinib (Tarceva) in combination with OSI-906 or placebo in chemo-naïve patients with advanced NSCLC with activating mutations of the epidermal growth factor receptor (EGFR) gene (2011-2013): Principal investigator
23. Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC) (2011-2015): Principal investigator
24. A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSA™ 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSA™ (2012-2016): Principal investigator
25. Phase 3, Randomized, Open-label Study of the Efficacy and Safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated East Asian Patients with Non-squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus (since 2012): Principal investigator
26. A phase II, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated non-small cell lung cancer previously treated with chemotherapy and crizotinib (2013-2016): Principal investigator
27. A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer (since 2013): Principal investigator

28. An Open-Label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC) (2013-2014): Principal investigator
29. A Randomized, Open-Label, Phase 3, Efficacy And Safety Study Of Dacomitinib (Pf-00299804) Versus Gefitinib For The First Line Treatment Of Locally Advanced Or Metastatic Non-Small Cell Lung Cancer In Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation(S) (since 2013): Principal investigator
30. A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib (since 2013): Principal investigator
31. A Global Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial of AMG706 in Combination with Paclitaxel and Carboplatin for Advanced Non-squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study) (since 2013): Co-investigator
32. An open label, multicentre, single-arm trial to assess the safety of afatinib for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) (since 2013): Co-investigator
33. A Phase II, Open Label, Single-arm, Study to Assess the Safety and Efficacy of AZD9291 in Patients with EGFRm+/T790M+, Locally Advanced or Metastatic NSCLC who have Progressed Following Prior Therapy with an approved Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor agent (since 2014): Principal investigator
34. Randomized, Multicenter, Phase III, Open-Label Study Of Alectinib Versus Crizotinib In Treatment-Naïve Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer (since 2014): Principal investigator

35. A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib (since 2014): Principal investigator
36. A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum- Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA3) (since 2014): Principal investigator
37. A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042) (since 2015): Principal investigator
38. A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 Positive Label (2015-2016): Principal investigator
39. A Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges (since 2015): Principal investigator
40. TIGER-1: A Randomized, Open-label, Phase 2/3 Study of CO-1686 or Erlotinib as First-line Treatment of Patients with EGFR-Mutant Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) (2015-2017): Principal investigator
41. A Phase 3 Randomized, Double-blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the First-line Treatment of Patients with Advanced Non-squamous Non-small Cell Lung Cancer (2015-2016): Principal investigator

42. A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) (since 2015): Principal investigator
43. A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (since 2016): Principal investigator
44. A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (since 2016): Principal investigator
45. A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer (AP26113-13-301) (since 2016): Principal investigator
46. Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy (since 2017): Principal investigator
47. XALT3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) (since 2017): Principal investigator

48. A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer (since 2017): Principal investigator
49. Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patients (since 2017): Principal investigator
50. A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial) (since 2017): Principal investigator
51. A Phase 3, Randomized, Open-Label Study of Lorlatinib (PF-06463922) Monotherapy Versus Crizotinib Monotherapy in the First-Line Treatment of Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (since 2018): Principal investigator

Recent invited lectures (in past 3 years)

- EGFR-driven advanced NSCLC: optimal first line treatment choices and what to do after progression. Roche Oncology Scientific Meeting, Penang, Malaysia. 7 Mar 2015.
- The first irreversible ErbB family blocker in the treatment of EGFR mutation positive NSCLC. BI evening symposium, Hong Kong, 23 April 2015.
- How I manage patients who develop acquired resistance to 1st line EGFR TKI. Meet-the-Expert round table meeting, Kuala Lumpur, Malaysia. 22 May 2015.
- How I treat EGFR mutation positive advanced NSCLC. AstraZeneca 1st National Oncology Summit, Kuala Lumpur, Malaysia. 23 May 2015.
- Updates in management of ALK positive NSCLC. Macau Chest Disease and Tuberculosis Association Annual Meeting, Macau. 13 Sep 2015.

- Immune-oncology: overview and update of current research and practice. Taiwan Clinical Oncology Society meeting, Taipei, Taiwan. 12 March 2016.
- Immuno-oncology in non-small cell lung cancer. Multi-specialty Medical Mega Conference Sixth Round, Hong Kong. 24 April 2016.
- A case of advanced lung adenocarcinoma with repeated liquid biopsy. Hong Kong Lung Cancer Study Group symposium, Hong Kong. 13 Aug 2016.
- NSCLC EGFR M+ Treatment Landscape; Adenocarcinoma NSCLC Treatment Landscape. Boehringer Ingelheim South East Asia & South Korea (SEASK) Lung Summit, South Korea. 19 and 20 Aug 2016.
- Experience with new targeted therapy in NSCLC at QMH. 3rd Hong Kong International Oncology Symposium, Hong Kong. 29 Oct 2016.
- Anti-PD1 therapy in NSCLC. MSD dinner symposium, Malaysian Oncology Society Annual Meeting, Johor, Malaysia. 11 Nov 2016.
- Recent update in ceritinib clinical trial and case sharing. Lung Cancer Expert Panel meeting, Novartis, Hong Kong. 26 Nov 2016.
- Latest advances in immunotherapy in NSCLC. The Macau Chest Disease and Tuberculosis Association Annual Scientific Meeting 2016, Macau. 3 Dec 2016.
- New generation EGFR TKI afatinib: data translated to clinical practice. PIPKRA Scientific Respiratory Meeting, Jakarta, Indonesia. 17 Feb 2017.
- New generation EGFR TKI afatinib: data translated to clinical practice. PERHOMPEDIN oncology meeting, Solo, Indonesia. 18 Feb 2017.
- How personalized NSCLC treatment is changing in 2017. Eli Lilly evening symposium, Hong Kong. 7 Mar 2017.

- Immuno-oncology at the forefront: emerging data in the treatment of lung cancer. Personalized Medicine in Oncology 2017 conference, hosted by Chiangmai University, Chiangmai, Thailand. 25 March 2017.
- Caveats in tumour re-biopsy in EGFR-mutated lung cancer. EGFR Diagnosis Multi-disciplinary Master-forum, AstraZeneca, Hong Kong. 8 April 2017.
- Resistance mechanisms and therapeutic strategies in ALK-rearranged NSCLC. CASECADE Regional KOL Meeting, Pfizer, Chiang Mai, Thailand. 29-30 April 2017.
- Pembrolizumab in 1L and 2L NSCLC. Expert Input Forum, MSD, Hong Kong. 6 May 2017.
- Is advanced lung cancer becoming a chronic disease? Invited lecture, Hospital Authority Convention 2017, Hong Kong. 17 May 2017.
- Clinical development programme: the AURA suite. Tagrisso launch symposium, AstraZeneca, Kuala Lumpur, Malaysia. 12 Aug 2017.
- Management of lung cancer: update on EGFR-targeted treatment. Meet-the-expert meeting for NSCLC, Boehringer Ingelheim, Hong Kong. 26 Sep 2017.
- The emerging role of immunotherapy as front-line treatment for advanced NSCLC. Macau Chest Diseases & Tuberculosis Association dinner symposium, Macau. 13 Oct 2017.
- Is immunotherapy practice changing in advanced lung cancer. HKAM Annual Scientific Meeting, Hong Kong. 22 Oct 2017.
- Diagnosis and treatment of tuberculosis in early stage lung cancer. Educational Session (invited speaker). ESMO-Asia, Singapore. 17 Nov 2017.

- PD-L1 and other biomarkers in immunotherapy. Korean Association for Lung Cancer annual meeting, Seoul, Korea. 24 Nov 2017.
- Personalized cancer immunotherapy – biomarkers. Current Trend Immuno-Oncology, MSD, Thailand. 2 Dec 2017.
- The breakthrough of IO in lung cancer treatment. Current Trend Immuno-Oncology, MSD, Thailand. 2 Dec 2017.

Selected publications (out of 98 published peer-reviewed papers and 12 book chapters)

1. **Ho JC**, Lam WK, Ooi GC, Wong MP, Lam B, Tsang KW. Chemotherapy for advanced lymphoepithelioma-like carcinoma of the lung. *Respiratory Medicine* 2000;94(10):943-947.
2. **Ho JC**, Zheng S, Comhair SA, Farver C, Erzurum SC. Differential expression of manganese superoxide dismutase and catalase in lung cancer. *Cancer Research* 2001; 61: 8578-8585.
3. **Ho JC**, Chan KN, Hu WH, Lam WK, Zheng L, Tipoe GL, Sun J, Leung R, and Tsang KW. The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia. *Am J Respir Crit Care Med* 2001; 163: 983-988.
4. Au WY, **Ho JC**, Lie AK, Sun J, Zheng L, Liang R, Lam WK, Tsang KW. Respiratory ciliary function in bone marrow recipients. *Bone Marrow Transplantation* 2001 June, 27(11):1147-1151.
5. Chan EC, Lam SY, Tsang KW, Lam B, **Ho JC**, Fu KH, Lam WK, Kwong YL. Aberrant promoter methylation in chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalveolar lavage. *Clin Cancer Res* 2002 Dec;8(12):3741-6.
6. Chan-Yeung M, Koo L, **Ho JCM**, Tsang KWT, Chan WS, Chiu SW, Ip MSM, Lam WK. Risk factors associated with lung cancer in Hong Kong. *Lung Cancer* 2003;40(2):131-140.

7. **Ho JC**, Tan EH, Leong SS, Wang CH, Sun Y, Li R, Wahid MIA, Jusuf A, Liao M, Guan Z, Handoyo P, Huang JS, Chan V, Luna G, Tsang KW, Lam WK. A multicenter phase II study of the efficacy and safety of docetaxel and cisplatin in Asian chemo-naïve patients with metastatic or locally advanced non-small cell lung cancer. *Respiratory Medicine* 2003;97:796-803.
8. **Ho JC**, Lam WK, Ooi GC, Wong MP, Lam JC, Ip MS, Tsang KW. Lymphoepithelioma-like carcinoma (LELC) of the lung in a patient with silicosis. *Eur Resp J* 2003;22:383-386.
9. Ooi GC, **Ho JCM**, Khong PL, Wong MP, Lam WK, Tsang KWT. Computed tomography characteristics of advanced primary pulmonary lymphoepithelioma-like carcinoma (LELC). *European Radiology* 2003;13:522-526.
10. **Ho JC**, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, Wong PC, Li PC, Ho PL, Lam WK, Ng CK, Ip MS, Lai KN, Chan-Yeung M, Tsang KW. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. *Am J Respir Crit Care Med* 2003;168:1449-1456.
11. Wong WM*, **Ho JC***, Ooi GC, Mok T, Chan J, Lai CL, Wu AY, Hung IF, Ng W, Lam YM, Tam WO, Wong BCY, Lam SK, Wong PC, Ho PL, Lam WK, Lai KN, Tsang KW. Liver function abnormality correlates with disease activity and severity of severe acute respiratory syndrome. *JAMA* 2003;290:2663-2665. (*co-first authors)
12. **Ho JC**, Lam WK, Wong MP, Wong MK, Ooi GC, Ip MS, Chan-Yeung M, Tsang KW. Lymphoepithelioma-like carcinoma of the lung: experience with ten cases. *Int J TB Lung Dis* 2004;8:890-895.
13. **Ho JC**, Wu AY, Lam B, Ooi GC, Khong PL, Ho PL, Chan-Yeung M, Zhong NS, Lam WK, Tsang KW. Pentaglobin in steroid-resistant severe acute respiratory syndrome. *Int J TB Lung Dis* 2004;8:1173-1179.

14. Chan-Yeung M, Tan-Un KC, Ip MS, Tsang KW, Ho SP, **Ho JC**, Chan H, Lam WK. Lung cancer susceptibility and polymorphisms of glutathione-S-transferase genes in Hong Kong. *Lung Cancer* 2004;45:155-160.
15. **Ho JC**, Mak JC, Ho SP, Ip MS, Tsang KW, Lam WK, Chan-Yeung M. Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels and lung cancer risk in Chinese in Hong Kong. *Journal of Thoracic Oncology* 2006;1:648-653.
16. **Ho JC**, Wong MP, Lam WK. Invited review: Lymphoepithelioma-like carcinoma of the lung. *Respirology* 2006;11:539-545.
17. **Ho JC**, Chan-Yeung M, Ho SP, Mak JC, Ip MS, Ooi GC, Wong MP, Tsang KW, Lam WK. Disturbance of systemic antioxidant profile in non-small cell lung carcinoma. *Eur Respir J* 2007;29:273-278.
18. Wong MK, Wong MP, Lam DC, Sihoe A, Cheng LC, Lam B, Ip MS, Nakajima T, Yasufuku K, Lam WK, **Ho JC**. Endobronchial ultrasound for diagnosis of synchronous primary lung cancers. *Lung Cancer* 2009;63:154-157.
19. **Ho JC**, Lam DC, Wong MK, Lam B, Ip MS, Lam WK. Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung. *Journal of Thoracic Oncology* 2009;4(9):1174-1177.
20. Wong MK, Lo AI, Lam B, Lam WK, Ip MS, **Ho JC**. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology* 2010;65(6):1023-1028.
21. Chiu PC, Liao S, Lam KK, Tang F, **Ho JC**, Ho PC, O WS, Yeung WS. Adrenomedullin regulates sperm motility and oviductal ciliary beat via cAMP/protein kinase A and nitric oxide. *Endocrinology* 2010;151:3336-3347.
22. Li HW, Liao SB, Chiu PC, Tam WW, **Ho JC**, Ng EH, Yeung WS, Tang F, O WS. Expression of adrenomedullin in human oviduct, its regulation by the hormonal cycle and

contact with spermatozoa, and its effect on ciliary beat frequency of the oviductal epithelium.

Journal of Clinical Endocrinology and Metabolism 2010;95:E18-25.

23. Liao SB, Ho JC, Tang F, O WS. Adrenomedullin increased ciliary beat frequency and decreased muscular contraction in the rat oviduct. *Reproduction* 2011;141(3):367-72.
24. Wong MK, Tam TC, Lam DC, Ip MS, Ho JC. EBUS-TBNA in patients presented with superior vena cava syndrome. *Lung Cancer* 2012;77(2):277-80.
25. Yam I, Lam DC, Chan K, Ho JC, Ip M, Lam WK, Chan TK, Chan V. EGFR array: uses in detection of plasma EGFR mutations in non-small cell lung cancer patients. *Journal of Thoracic Oncology* 2012 ;7:1131-1140.
26. Siu CW, Wong MP, Ho CM, Lam CL, Tse HF. Fatal lung toxicity related to dronedarone. *Archive of Internal Medicine* 2012;172(6):516-517.
27. Liao SB, LI HWR, Ho JC, Yeung WSB, Ng EHY, Cheung ANY, Tang F, O WS. Possible role of adrenomedullin in the pathogenesis of tubal ectopic pregnancy. *Journal of Clinical Endocrinology and Metabolism* 2012;97(6):2105-2112.
28. Lee CK, Brown C, Gralla R, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu DT, Zaatari A, Sanchez JO, Vu VV, Au JS, Inoue A, Lee SM, GebSKI V, Yang JC. Impact of epidermal growth factor receptor inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. *J Natl Cancer I* 2013;105(9):595-605.
29. Thompson P, Salvi S, Lin J, Cho YJ, Eng P, Manap RA, Boonsawat W, Hsu JY, Faruqi RA, Moreno-Cantu JJ, Fish JE, Ho JC. Insights, attitudes, and perceptions about asthma and its treatment: Findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong. *Respirology* 2013;18(6):957-67.
30. Li YY, Lam SK, Mak JC, Zheng CY, Ho JC. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. *Lung Cancer* 2013;81(3):354-61.
31. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B,

- Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahrudin E, Qian X, **Ho JC**, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok TS. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small cell lung cancer. *Lancet Oncol* 2013;14(8):777-86.
32. Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, **Ho JC**. Combination of arsenic trioxide and chemotherapy in small cell lung cancer. *Lung Cancer* 2013;82(2):222-30.
33. Lam SK, Mak JC, Zheng CY, Li YY, Kwong YL, **Ho JC**. Downregulation of thymidylate synthase with arsenic trioxide lung adenocarcinoma. *Int J Oncol* 2014;44(6):2093-102.
34. Lam SK, Li YY, Zheng CY, Leung LL, **Ho JC**. E2F1 downregulation by arsenic trioxide in lung adenocarcinoma. *Int J Oncol* 2014;45:2033-43.
35. Lam SK, Li YY, Zheng CY, **Ho JC**. Downregulation of E2F1 by arsenic trioxide in mesothelioma. *Int J Oncol* 2015;46:113-22.
36. Liam CK, Andarini S, Lee P, **Ho JC**, Chau NQ, Tscheikuna J. Lung cancer staging now and in the future. *Respirology* 2015;20:526-34.
37. Zheng CY, Lam SK, Li YY, **Ho JC**. Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity. *Int J Oncol* 2015;46:1067-78.
38. Li YY, Lam SK, Zheng CY, **Ho JC**. The effect of tumor microenvironment on autophagy and sensitivity to targeted therapy in EGFR-mutated lung adenocarcinoma. *J Cancer* 2015;6(4):382-386.
39. Wang Z, Seow WJ, Shiraishi K, Hsiung CA, Matsuo K, Liu J, Chen K, Yamji T, Yang Y, Chang IS, Wu C, Hong YC, Burdett L, Wyatt K, Chung CC, Li SA, Yeager M, Hutchinson A, Hu W, Caporaso N, Landi MT, Chatterjee N, Song M, Fraumeni JF Jr, Kohno T, Yokota J, Kunitoh H, Ashikawa K, Momozawa Y, Daigo Y, Mitsudomi T, Yatabe Y, Hida T, Hu Z, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Yin Z, Li X, Ren Y, Guan P, Chang J, Tan W, Chen CJ, Chang GC, Tsai YH, Su WC, Chen KY, Huang MS, Chen YM, Zheng H, Li H, Cui

- P, Guo H, Xu P, Liu L, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Park JY, Kim YH, Sung JS, Park KH, Kim YT, Jung YJ, Kang CH, Park IK, Kim HN, Jeon HS, Choi JE, Choi YY, Kim JH, Oh IJ, Kim YC, Sung SW, Kim JS, Yoon HI, Kweon SS, Shin MH, Seow A, Chen Y, Lim WY, Liu J, Wong MP, Lee VH, Bassig BA, Tucker M, Berndt SI, Chow WH, Ji BT, Wang J, Xu J, Sihoe AD, **Ho JC**, Chan JK, Wang JC, Lu D, Zhao X, Zhao Z, Wu J, Chen H, Jin L, Wei F, Wu G, An SJ, Zhang XC, Su J, Wu YL, Gao YT, Xiang YB, He X, Li J, Zheng W, Shu XO, Cai Q, Klein R, Pao W, Lawrence C, Hosgood HD 3rd, Hsiao CF, Chien LH, Chen YH, Chen CH, Wang WC, Chen CY, Wang CL, Yu CJ, Chen HL, Su YC, Tsai FY, Chen YS, Li YJ, Yang TY, Lin CC, Yang PC, Wu T, Lin D, Zhou B, Yu J, Shen H, Kubo M, Chanock SJ, Rothman N, Lan Q. Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. *Hum Mol Genet* 2016;25(3):620-9.
40. Bai CX, Choi CM, Chu CM, Anantham D, **Ho JC**, Khan AZ, Lee JM, Li SY, Saenghirunvattana S, Yim A. Evaluation of pulmonary nodules: clinical practice consensus guidelines for Asia. *Chest* 2016; 150(4):877-893.
41. Lam SK, Leung LL, Li YY, Zheng CY, **Ho JC**. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma. *Lung Cancer* 2016;100:111-119.
42. Seow WJ, Matsuo K, Hsiung CA, Shiraishi K, Song M, Kim HN, Wong MP, Hong YC, Hosgood HD 3rd, Wang Z, Chang IS, Wang JC, Chatterjee N, Tucker M, Wei H, Mitsudomi T, Zheng W, Kim JH, Zhou B, Caporaso NE, Albanes D, Shin MH, Chung LP, An SJ, Wang P, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Bassig BA, Chang J, **Ho JC**, Ji BT, Kubo M, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Sakamoto H, Kunitoh H, Tsuta K, Watanabe SI, Nokihara H, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Shi J, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Wong JY, Matsuda F, Su J, Kim YH, Oh IJ, Song F, Lee VH, Su

WC, Chen YM, Chang GC, Chen KY, Huang MS, Yang PC, Lin HC, Xiang YB, Seow A, Park JY, Kweon SS, Chen CJ, Li H, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Wang WC, Chung CC, Lawrence C, Burdett L, Yeager M, Jacobs KB, Hutchinson A, Berndt SI, He X, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Hu L, Chen CH, Yang TY, Xu J, Guan P, Tan W, Wang CL, Sihoe AD, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Chan JK, Chu M, Li YJ, Li J, Chen H, Yu CJ, Jin L, Lo YL, Chen YH, Fraumeni JF Jr, Liu J, Yamaji T, Yang Y, Hicks B, Wyatt K, Li SA, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Li X, Ren Y, Cui P, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Wu G, Chien LH, Chen HL, Su YC, Tsai FY, Chen YS, Yu J, Stevens VL, Laird-Offringa IA, Marconett CN, Lin D, Chen K, Wu YL, Landi MT, Shen H, Rothman N, Kohno T, Chanock SJ, Lan Q. Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. *Hum Mol Genet* 2016 Dec 26. pii: ddw414. doi: 10.1093/hmg/ddw414.

43. **Ho JC**, Lam SK. Combining arginine depletion and chemotherapy in thoracic malignancies. *J Clin Oncol* 2017;35(16):1758-1759.
44. Lam SK, Li YY, Xu S, Leung LL, U KP, Zheng YF, Cheng PN, **Ho JC**. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts. *Respir Res* 2017;18(1):80.
45. Han L, Lee CK, Pang H, Chan HT, Lo IL, Lam SK, Cheong TH, **Ho JC**. Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status. *Lung Cancer* 2017;114:79-89.